Cardlytics (NASDAQ:CDLX) Rating Increased to Strong-Buy at Craig Hallum

Craig Hallum upgraded shares of Cardlytics (NASDAQ:CDLX) from a hold rating to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

A number of other equities analysts have also recently weighed in on CDLX. Evercore ISI began coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $4.00 to $3.50 in a research report on Thursday, August 15th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and decreased their price target for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.92.

Cardlytics Stock Up 7.4 %

Shares of NASDAQ CDLX opened at $4.37 on Wednesday. The company has a 50 day simple moving average of $3.69 and a 200-day simple moving average of $6.66. The company has a market capitalization of $222.09 million, a P/E ratio of -0.72 and a beta of 1.61. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. Cardlytics has a 1 year low of $2.89 and a 1 year high of $20.52.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 93.64%. The business’s revenue was down 15.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.26) EPS. On average, equities research analysts predict that Cardlytics will post -1.72 earnings per share for the current year.

Insider Transactions at Cardlytics

In other news, Director Scott A. Hill acquired 40,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, with a total value of $143,200.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $143,200. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Scott A. Hill purchased 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at $143,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 43,573 shares of company stock valued at $151,612. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CDLX. GSA Capital Partners LLP increased its stake in Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the period. Renaissance Technologies LLC increased its stake in shares of Cardlytics by 711.9% during the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after acquiring an additional 307,800 shares during the period. Kent Lake Capital LLC acquired a new position in shares of Cardlytics during the first quarter worth about $3,622,000. Perbak Capital Partners LLP acquired a new position in shares of Cardlytics during the first quarter worth about $2,348,000. Finally, Blackstone Inc. acquired a new position in shares of Cardlytics during the first quarter worth about $2,029,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.